Cabot Oil & Gas Corporation (COG) traded within a range of $21.5 to $21.75 after opening the day at $21.53. The company has seen its stock decrease in value by -7.23% so far this year. The stock was down close to -0.18% on light volume in last trading session and closed at $21.67 per share. After the recent fall, the stock is currently holding -18.88% below its 52 week high of $26.74 and 37.48% above its 12-month low of $16.87. The shares are down by over -1.09% in the last three months, and the RSI indicator value of 42.84 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with approximately 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with approximately 85,500 net acres in the oil window of the play. It also transports, stores, gathers, and purchases natural gas for resale. The company sells its natural gas to industrial customers, local distribution companies, and gas marketers through gathering systems and pipelines, as well as to intrastate pipelines, natural gas processors, and marketing companies. As of December 31, 2015, it had proved reserves of approximately 8,190 billion cubic feet of natural gas equivalent. The company was founded in 1989 and is headquartered in Houston, Texas.
Bristol-Myers Squibb Company (BMY) failed to extend gains with the stock declining -0.37% or $-0.21 to close the day at $56.07 on active trading volume of 6.64M shares, compared to its three month average trading volume of 10.1M. The New York New York 10154 based company has been underperforming the drug manufacturers – major group over the past 52 weeks, with the stock losing -9.08%, compared to the industry which has advanced 6.51% over the same period. With RSI of 38.37, the stock should still continue to rise and get closer to its one year target estimate of $62.53, making it a hold for now.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Hanesbrands Inc. (HBI) dropped $-0.85 to close the day at a new closing price of $22.01, a -3.72% decrease in value from its previous closing price that moved the stock 2.85% above its 52 week low of $21.4. A total of 6.62M shares exchanged hands during the day compared with its three month average trading volume of 6.09M. The stock, which fluctuated between $21.93 and $23 during the day, currently situated -28.61% below its 52 week high. The stock is down by -0.32% in the past one month and down by -8.49% over the past three months. With a one year target estimate of $32 and RSI of 42.86, the stock still has upside potential, making it a hold for now.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells various basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International. It sells bras, panties, shapewears, hosiery, mens underwear, childrens underwear, and socks; and other activewear, such as T-shirts, fleece, sport shirts, performance T-shirts and shorts, sports bras, and thermals, as well as licensed logo apparel in collegiate bookstores and other channels. The company licenses its Champion name for footwear and sports accessories. It provides its products primarily under the Maidenform, Bali, Playtex, Hanes, JMS/Just My Size, Lilyette, Wonderbra, Donna Karan, DKNY, Champion, Polo Ralph Lauren, L’eggs, Hanes Beefy-T, Gear for Sports, Duofold, DIM, Nur Die/Nur Der, Lovable, Shock Absorber, Abanderado, Zorba, Rinbros, Kendall, Sol y Oro, Fila, Bellinda, Edoo, and Track N Field brand names. The company markets its products through retailers, wholesalers, and third party embellishers, as well as directly to consumers. As of January 2, 2016, it operated 252 outlet stores in the United States; and Websites under the Hanes, One Hanes Place, JMS/Just My Size, Champion, and Maidenform names. The company also sells its products in Europe, Asia, Latin America, Canada, Australia, the Middle East, Africa, and the Caribbean. Hanesbrands Inc. was founded in 2005 and is headquartered in Winston-Salem, North Carolina.